This paper is in the following e-collection/theme issue:

Infodemiology and Infoveillance (1274)

Published on in Vol 16, No 5 (2014): May

Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse

Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse

Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse

Authors of this article:

Emily C McNaughton1 ;   Paul M Coplan2, 3 ;   Ryan A Black4 ;   Sarah E Weber1 ;   Howard D Chilcoat2, 5 ;   Stephen F Butler1
Article Authors Cited by (24) Tweetations (12) Metrics

Journals

  1. Loeser K, Rodriguez R. Regulatory and evidence-based considerations for abuse-deterrent opioids. American Journal of Health-System Pharmacy 2019;76(2):114 View
  2. Coplan P, Chilcoat H, Butler S, Sellers E, Kadakia A, Harikrishnan V, Haddox J, Dart R. The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting. Clinical Pharmacology & Therapeutics 2016;100(3):275 View
  3. Jones M, Carney M, Kaye R, Prabhakar A, Kaye A. Drug Formulation Advances in Extended-Release Medications for Pain Control. Current Pain and Headache Reports 2016;20(6) View
  4. Maincent J, Zhang F. Recent advances in abuse-deterrent technologies for the delivery of opioids. International Journal of Pharmaceutics 2016;510(1):57 View
  5. Vosburg S, Haynes C, Besharat A, Green J. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction‐Related Surveillance (RADARS) System Web Monitoring Program. Pharmacoepidemiology and Drug Safety 2017;26(9):1044 View
  6. Gudin J, Levy-Cooperman N, Kopecky E, Fleming A. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Pain Medicine 2015;16(11):2142 View
  7. Anderson L, Bell H, Gilbert M, Davidson J, Winter C, Barratt M, Win B, Painter J, Menone C, Sayegh J, Dasgupta N. Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis. JMIR Public Health and Surveillance 2017;3(1):e6 View
  8. Jones C, Muhuri P, Lurie P. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013. The Clinical Journal of Pain 2017;33(5):452 View
  9. Webster L, Pantaleon C, Iverson M, Smith M, Kinzler E, Aigner S. Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. Pain Research and Management 2018;2018:1 View
  10. Chisholm-Burns M, Spivey C, Sherwin E, Wheeler J, Hohmeier K. The opioid crisis: Origins, trends, policies, and the roles of pharmacists. American Journal of Health-System Pharmacy 2019;76(7):424 View
  11. Sarker A, DeRoos A, Perrone J. Mining social media for prescription medication abuse monitoring: a review and proposal for a data-centric framework. Journal of the American Medical Informatics Association 2020;27(2):315 View
  12. R. Scott K, Nelson L, Meisel Z, Perrone J. Opportunities for Exploring and Reducing Prescription Drug Abuse Through Social Media. Journal of Addictive Diseases 2015;34(2-3):178 View
  13. Severtson S, Ellis M, Kurtz S, Rosenblum A, Cicero T, Parrino M, Gilbert M, Buttram M, Dasgupta N, BucherBartelson B, Green J, Dart R. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug and Alcohol Dependence 2016;168:219 View
  14. Peacock A, Degenhardt L, Hordern A, Larance B, Cama E, White N, Kihas I, Bruno R. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. International Journal of Drug Policy 2015;26(12):1265 View
  15. Butler S, McNaughton E, Black R, Cassidy T. Evaluation of the Relative Abuse of an OROS Extended-release Hydromorphone HCI Product. The Clinical Journal of Pain 2018;34(7):618 View
  16. Gasior M, Bond M, Malamut R. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgraduate Medicine 2016;128(1):85 View
  17. Sellers E, Shram M, Schoedel K. The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond. Pharmaceutical Medicine 2014;28(6):317 View
  18. Sarker A, O’Connor K, Ginn R, Scotch M, Smith K, Malone D, Gonzalez G. Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter. Drug Safety 2016;39(3):231 View
  19. Brennan M, Kopecky E, Marseilles A, O’Connor M, Fleming A. The Comparative Pharmacokinetics of Physical Manipulation by Crushing of Xtampza ® ER Compared with OxyContin ®. Pain Management 2017;7(6):461 View
  20. Litman R, Pagán O, Cicero T. Abuse-deterrent Opioid Formulations. Anesthesiology 2018;128(5):1015 View
  21. Butler S, Oyedele N, Dailey Govoni T, Green J. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users. JMIR Public Health and Surveillance 2020;6(1):e16038 View
  22. Harder V, Varni S, Murray K, Plante T, Villanti A, Wolfson D, Maruti S, Fairfield K. Prescription opioid policies and associations with opioid overdose and related adverse effects. International Journal of Drug Policy 2021;97:103306 View

Books/Policy Documents

  1. Buller D, Walkosz B, Gill Woodall W. Prevention of Substance Use. View
  2. McAninch J, Secora A, Kornegay C, Staffa J. Pharmacoepidemiology. View